Abstract
The coronavirus disease-2019 (COVID-19) pandemic has resulted in a proliferation of clinical trials designed to slow the spread of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Many therapeutic agents that are being used to treat patients with COVID-19 are repurposed treatments for influenza, Ebola, or for malaria that were developed decades ago and are unlikely to be familiar to the cardiovascular and cardio-oncology communities. Here, we provide a foundation for cardiovascular and cardio-oncology physicians on the front line providing care to patients with COVID-19, so that they may better understand the emerging cardiovascular epidemiology and the biological rationale for the clinical trials that are ongoing for the treatment of patients with COVID-19.
Original language | English |
---|---|
Pages (from-to) | 254-269 |
Number of pages | 16 |
Journal | JACC: CardioOncology |
Volume | 2 |
Issue number | 2 |
DOIs | |
State | Published - Jun 2020 |
Keywords
- ACE2
- COVID-19
- SARS-CoV-2
- clinical trials
- renin angiotensin system